Table 1.

New generation anti-CD20 mAbs in clinical development.

Antibody	Characteristics	Activity compared with rituximab	Phase of development
Ofatumumab	Type I, fully human	Increased CDC and slower off-rate	FDA approved for CLL and phase III trials in NHL
Veltuzumab	Type I, humanized	Slower off-rate	Phase I/II of subcutaneous administration in NHL and CLL
Ocrelizumab	Type I, humanized	Increased ADCC and lower CDC	Phase II in NHL
PR0131921	Type I, humanized with modified Fc	Increased ADCC	Phase I/II in NHL
AME-133v	Type I, humanized with modified Fc	Increased ADCC	Phase I/II in NHL
GA101	Type II, humanized with glyco-engineered Fc	Increased ADCC and direct PCD	Phase III in NHL and in DLBCL